SNYClinical Trials•globenewswire•
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Sentiment:Positive (80)
Summary
(NASDAQ:SNY) Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by globenewswire